Pinebridge Investments L.P. Lowers Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Pinebridge Investments L.P. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 112,625 shares of the medical research company's stock after selling 23,584 shares during the period. Pinebridge Investments L.P. owned about 0.22% of Charles River Laboratories International worth $20,791,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc increased its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after buying an additional 65 shares during the last quarter. GeoWealth Management LLC increased its holdings in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $48,000. Finally, Tortoise Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. UBS Group reiterated a "neutral" rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Barclays cut their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $182.00.

Insider Activity at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Up 1.9 %

Shares of NYSE CRL traded up $2.17 during midday trading on Tuesday, reaching $117.25. 250,004 shares of the company's stock traded hands, compared to its average volume of 921,383. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock's 50 day simple moving average is $145.74 and its 200-day simple moving average is $170.44. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a market cap of $5.76 billion, a price-to-earnings ratio of 782.04, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the firm earned $2.46 earnings per share. The company's quarterly revenue was down 1.1% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).